The Latest Advances in Otoprotective Agents with Ting Therapeutics

Jian Zuo, CEO of Ting Therapeutics, discusses the latest updates on otoprotective agents for three conditions: antibiotic-induced hearing loss, cisplatin-induced hearing loss, and noise-induced hearing loss. Dr. Zuo explains the science behind the company's innovative drug candidates and how they aim to address the unmet need for hearing protection.

Zuo provides an overview of Ting Therapeutics’ preclinical research, outlining key findings on TT003 and other investigational compounds. The discussion focuses on the company's research process, detailing the progress of these drug candidates through preclinical testing and examining their potential relevance for patients at risk of hearing loss.

Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter):

TIMESTAMPS
00:00 Introduction
01:16 Background and mission of Ting Therapeutics
04:24 Identifying potential otoprotective drugs
07:15 SBIR phase II grant to prevent antibiotic-induced hearing loss
11:41 Treating noise and cisplatin-induced hearing loss (TT001 & TT002)
16:45 Exploring how otoprotective agents might work in a clinical setting
21:44 Future vision for Ting Therapeutics
25:36 How should clinicians think about otoprotective agents?